Precigen (PGEN) Stock: Buy, Sell, or Hold?
PGEN - Precigen, Inc. Common Stock
$6.19
-0.20 (-3.13%)
▼
5d:
-3.05%
30d:
-19.61%
90d:
+14.21%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When PGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$19.17
67.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PGEN is currently trading at $6.19, which is considered oversold relative to its 30-day fair value range of $6.86 to $8.05. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.8) compared to its historical average (31.4). Remarkably, the market is currently pricing in an annual earnings decline of 32.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PGEN is in a strong uptrend. The price is currently testing key support at $6.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.65 (+120.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PGEN is in a strong uptrend. The price is currently testing key support at $6.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.65 (+120.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.86 -
$8.05
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding PGEN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 120.5% below Wall St target ($13.65)
- NEUTRAL: Bottoming setup forming (50/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$6.86 -
$8.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.15
Resistance Level
$7.87
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.76
Wall Street Target
$13.65
(+120.5%)
Revenue Growth (YoY)
6322.7%
Profit Margin
-184.0%
Valuation Discount vs History
-32.3% cheaper
PE vs Historical
9.8 vs 31.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-32.3%
(market-implied from PE analysis)
1-Year Target
$5.57
(-10%)
2-Year Target
$5.01
(-19%)
3-Year Target
$4.51
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→31)
$14.52
(+135%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 184.8%)
$42.52
(+587%)
Base:
(SPY PE: 9.8, Growth: 184.8%)
$20.89
(+238%)
Bear:
(PE: 8.3, Growth: 184.8%)
$17.76
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 31.4
Stabilization Target:
$19.92
(+221.8%)
PE Expansion Potential:
+221.8%
Share & Embed Analysis
Last updated: October 24, 2026 2:57 AM ET
Data refreshes hourly during market hours. Next update: 3:57 AM
Data refreshes hourly during market hours. Next update: 3:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 47 HOLD |
Advanced PGEN Option Strategies
Professional options setups generated by AI based on today's PGEN price and gamma walls.
